^
    17h
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Ruijin Hospital
    New P3 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    doxorubicin hydrochloride • cyclophosphamide
    21h
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    22h
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    1d
    Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (clinicaltrials.gov)
    P=N/A, N=30, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    1d
    Sanguinarine Induces ROS-Mediated Mitochondrial Dysfunction and Inhibits AKT/GSK3 Signaling to Potentiate Apoptotic Effects in Cutaneous T-Cell Lymphoma. (PubMed, Phytother Res)
    Synergistic effects with bortezomib (BTZ) were analyzed...SNG exerts potent anticancer effects in CTCL by inducing ROS-dependent mitochondrial apoptosis and inhibiting the PI3K/AKT/GSK3 signaling pathway. Its synergy with BTZ and computational validation of AKT/Bcl-2 targeting underscore its potential as a novel therapeutic candidate for CTCL, warranting further preclinical investigation.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis)
    |
    bortezomib
    1d
    CAR T-cells in hematologic malignancies: Advances, challenges, and future directions. (PubMed, iScience)
    Integration of artificial intelligence and point-of-care manufacturing may further streamline production and patient selection. Continued innovation will determine the long-term impact of CAR T-cell therapy as a scalable pillar of precision hematologic oncology.
    Review • Journal
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    1d
    Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders. (PubMed, Pharmacol Res)
    Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib)...Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
    FDA event • Review • Journal
    |
    BTK (Bruton Tyrosine Kinase) • PLCG2 (Phospholipase C Gamma 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase)
    |
    Imbruvica (ibrutinib) • imatinib • cyclophosphamide • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • vincristine • prednisone • Jaypirca (pirtobrutinib) • Rhapsido (remibrutinib)
    1d
    Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma via inhibition of the AKT-SKP2 axis. (PubMed, Toxicol Appl Pharmacol)
    Notably, PS elevated intracellular reactive oxygen species (ROS), and scavenging ROS with N-acetylcysteine (NAC) significantly attenuated PS-driven cytotoxicity, supporting a ROS-dependent mechanism. Finally, PS combined with the proteasome inhibitor bortezomib produced greater anti-CTCL activity than either agent alone, consistent with a synergistic interaction. Together, these findings show that PS promotes ROS-dependent, mitochondria-mediated apoptosis in CTCL and support further evaluation of PS-based strategies for this malignancy.
    Journal
    |
    XIAP (X-Linked Inhibitor Of Apoptosis) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SKP2 (S-phase kinase-associated protein 2)
    |
    bortezomib
    3d
    The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review. (PubMed, Expert Rev Hematol)
    Amplification of 9p24.1, causing PD-L1 overexpression, plays a significant role in EBV-positive DLBCL and EBV-positive cHL, whereas EBVMCU, DLBCL-CI, FA-DLBCL, and LyG primarily depend on an (local) immunosuppressive condition. In conclusion, the molecular pathogenesis of EBV LPD is less reliant on driver mutations and instead rely on EBV latent genes and immune evasion; both factors provide promising targets for future therapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    PD-L1 overexpression
    3d
    miR-193-5p, miR-1307-5p, and miR-671-5p: Potential biomarkers for chemoresistance in diffuse large B-cell lymphoma. (PubMed, Indian J Med Res)
    In vitro proteomics showed their impact on key oncogenic pathways, revealing significant enrichment of replication and transcription-related proteins. Interpretation and conclusions The expression of miR-193b-5p, miR-1307-5p, and miR-671-5p miRNAs in diffuse large B-cell lymphoma tissues may serve as predictive biomarkers.
    Review • Journal
    |
    MIR193B (MicroRNA 193b) • MIR671 (MicroRNA 671)
    4d
    Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)